Oncology
Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？
By MedXY|Oct 5, 2025
An 18-month course of rivaroxaban significantly lowers recurrent venous thromboembolism compared to 6 months in cancer patients with low-risk pulmonary embolism without a substantial increase in major bleeding risk.